Characteristics | All | ≤ 64 years | 65–74 years | ≥ 75 years | P | ||||
---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | ||
452 | 100.0 | 183 | 40.5 | 178 | 39.4 | 91 | 20.1 | ||
Symptoms at diagnosis | Â | Â | Â | Â | Â | Â | Â | Â | 0.024 |
 Yes | 103 | 28.5 | 35 | 23.8 | 38 | 26.8 | 30 | 41.1 |  |
 No | 259 | 71.5 | 112 | 76.2 | 104 | 73.2 | 43 | 58.9 |  |
 Unknown | 90 | – | 36 | – | 36 | – | 18 | – |  |
Clinical stage at diagnosis | Â | Â | Â | Â | Â | Â | Â | Â | 0.0837 |
 T1N0M0 | 168 | 43.6 | 78 | 49.1 | 63 | 41.4 | 27 | 36.5 |  |
 T2N0M0 | 121 | 31.4 | 46 | 28.9 | 48 | 31.6 | 27 | 36.5 |  |
 T3/T4N0M0 | 43 | 11.2 | 22 | 13.8 | 15 | 9.9 | 6 | 8.1 |  |
 N+/M+ | 53 | 13.8 | 13 | 8.2 | 26 | 17.1 | 14 | 18.9 |  |
 Unknown | 67 | – | 24 | – | 26 | – | 17 | – |  |
Prostate Specific Antigen (ng/ml) | Â | Â | Â | Â | Â | Â | Â | Â | 0.17 |
 <  4 | 19 | 4.2 | 12 | 6.6 | 4 | 2.2 | 3 | 3.3 |  |
 4 ≥ PSA > 10 | 263 | 58.2 | 115 | 62.8 | 102 | 57.3 | 46 | 50.5 |  |
 10 ≥ PSA > 20 | 95 | 21.0 | 30 | 16.4 | 43 | 24.2 | 22 | 24.2 |  |
 20 ≥ PSA > 100 | 46 | 10.2 | 17 | 9.3 | 17 | 9.6 | 12 | 13.2 |  |
 ≥ 100 ng/ml | 29 | 6.4 | 9 | 4.9 | 12 | 6.7 | 8 | 8.8 |  |
Gleason grade group | Â | Â | Â | Â | Â | Â | Â | Â | 0.003 |
 Group 1 (3 + 3) | 152 | 34.0 | 79 | 43.7 | 56 | 31.8 | 17 | 18.9 |  |
 Group 2 (3 + 4) | 117 | 26.2 | 46 | 25.4 | 45 | 25.5 | 26 | 28.9 |  |
 Group 3 (4 + 3) | 84 | 18.8 | 31 | 17.1 | 36 | 20.5 | 17 | 18.9 |  |
 Group 4 (8) | 48 | 10.7 | 13 | 7.2 | 19 | 10.8 | 16 | 17.8 |  |
 Group 5 (9 or 10) | 46 | 10.3 | 12 | 6.6 | 20 | 11.4 | 14 | 15.5 |  |
 Unknown | 5 | – | 2 | – | 2 | – | 1 | – |  |
Risk groups | Â | Â | Â | Â | Â | Â | Â | Â | 0.0129 |
 Low | 69 | 17.9 | 40 | 25.2 | 22 | 14.5 | 7 | 9.5 |  |
 Intermediate | 140 | 36.4 | 57 | 35.8 | 58 | 38.1 | 25 | 33.8 |  |
 High | 123 | 31.9 | 49 | 30.8 | 46 | 30.3 | 28 | 37.8 |  |
 Regional/metastatic | 53 | 13.8 | 13 | 8.2 | 26 | 17.1 | 14 | 18.9 |  |
 Unknown | 67 | – | 24 | – | 26 | – | 17 | – |  |